Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-01-04
2011-01-04
McIntosh, III, Traviss C (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07863254
ABSTRACT:
The invention provides methods for treating or preventing psychiatric and substance abuse disorders, involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-containing, or adenosine-elevating compound to a mammal.
REFERENCES:
patent: 4027017 (1977-05-01), Hata et al.
patent: 4048316 (1977-09-01), Penn
patent: 4115576 (1978-09-01), Penn
patent: 4386077 (1983-05-01), Borgo
patent: 4704361 (1987-11-01), Miccoli et al.
patent: 4764603 (1988-08-01), Zappia et al.
patent: 4999382 (1991-03-01), Wurtman et al.
patent: 5179126 (1993-01-01), Wurtman et al.
patent: 5278176 (1994-01-01), Lin
patent: 5409946 (1995-04-01), Garvey et al.
patent: 5472958 (1995-12-01), Gunn, Jr. et al.
patent: 5635486 (1997-06-01), Yamamoto et al.
patent: 5691320 (1997-11-01), von Borstel et al.
patent: 5691365 (1997-11-01), Crooks et al.
patent: 5888532 (1999-03-01), Pritsos et al.
patent: 5919789 (1999-07-01), Dyke et al.
patent: 5958896 (1999-09-01), Renshaw et al.
patent: 5977174 (1999-11-01), Bradley et al.
patent: 6103703 (2000-08-01), Renshaw et al.
patent: 6132724 (2000-10-01), Blum
patent: 6153653 (2000-11-01), Shashoua
patent: 6258794 (2001-07-01), Renshaw
patent: 6277855 (2001-08-01), Yerxa
patent: 6284268 (2001-09-01), Mishra et al.
patent: 6319953 (2001-11-01), Carlson et al.
patent: 6331568 (2001-12-01), Horrobin
patent: 6410522 (2002-06-01), Ruenberg
patent: 6503951 (2003-01-01), Pischel et al.
patent: 6541043 (2003-04-01), Lang
patent: 6608064 (2003-08-01), McLean et al.
patent: 6624195 (2003-09-01), Horrobin
patent: 6696495 (2004-02-01), Mueller
patent: 6706764 (2004-03-01), Kaddurah-Daouk et al.
patent: 6727231 (2004-04-01), Page et al.
patent: 6852870 (2005-02-01), Stoll
patent: 6989376 (2006-01-01), Watkins et al.
patent: 7026301 (2006-04-01), Cardozo et al.
patent: 7053064 (2006-05-01), Lukas
patent: 7601701 (2009-10-01), Lukas
patent: 2002/0019364 (2002-02-01), Renshaw
patent: 2002/0028787 (2002-03-01), Watkins et al.
patent: 2002/0182196 (2002-12-01), McCleary
patent: 2003/0100844 (2003-05-01), Miller et al.
patent: 2003/0114415 (2003-06-01), Wurtman et al.
patent: 2003/0220291 (2003-11-01), Renshaw
patent: 2003/0224435 (2003-12-01), Seiwert
patent: 2003/0232827 (2003-12-01), Meltzer et al.
patent: 2004/0102419 (2004-05-01), Kaddurah-Daouk et al.
patent: 2004/0167093 (2004-08-01), Lukas
patent: 2004/0176316 (2004-09-01), Renshaw et al.
patent: 2004/0192732 (2004-09-01), Pratt et al.
patent: 2004/0266659 (2004-12-01), LaBerge
patent: 2005/0113449 (2005-05-01), Renshaw
patent: 2005/0129710 (2005-06-01), Renshaw et al.
patent: 2006/0128671 (2006-06-01), Kaddurah-Daouk et al.
patent: 2006/0217344 (2006-09-01), Lukas
patent: 2008/0132472 (2008-06-01), Renshaw
patent: 2008/0300214 (2008-12-01), Lukas et al.
patent: 2009/0054370 (2009-02-01), Renshaw
patent: 2009/0215714 (2009-08-01), Renshaw et al.
patent: 2010/0041620 (2010-02-01), Renshaw et al.
patent: 2010/0041621 (2010-02-01), Renshaw et al.
patent: 3400276 (1985-07-01), None
patent: 0 188647 (1986-07-01), None
patent: 0218190 (1987-04-01), None
patent: 0218190 (1989-11-01), None
patent: 0 431 758 (1991-06-01), None
patent: 0615750 (1994-09-01), None
patent: 63-208524 (1988-08-01), None
patent: 2-500372 (1990-02-01), None
patent: 08-183737 (1996-07-01), None
patent: 2128653 (1999-04-01), None
patent: WO 89/03837 (1989-05-01), None
patent: WO 93/14076 (1993-07-01), None
patent: WO 99/26620 (1999-06-01), None
patent: WO 00/06174 (2000-02-01), None
patent: WO 00/11952 (2000-03-01), None
patent: WO 01/44265 (2001-06-01), None
patent: WO 01/72288 (2001-10-01), None
patent: WO 02/45583 (2002-06-01), None
patent: WO 02/088159 (2002-11-01), None
Page et al., Proc. Natl Acad Sci USA, Oct. 1997,vol. 94(21), pp. 11601-11606.
Secades et al., Methods Find Exp Clin Pharmacol., vol. 17 Suppl B, Oct. 1995, pp. 1-54 (abstract provided with relevant teachings).
Shekim et al., Psychopharmacol Bull. 1990;26(2):249-53.
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill Medical Publishing Division, 2001, pp. 54-56, 57.
US Surgeon General, “Overview of ADHD and its Treatments”, US Office of the Surgeon General, Mental Health Matters, 2000-2001, pp. 1-6.
Carlezon et al., “Antidepressant-Like Effects of Cytidine in the Forced Swim Test in Rats,”Biol. Psychiatry51:882-889 (2002).
Pleul et al., “Lithium Therapy and the Turnover of Phosphatidylcholine in Human Erythrocytes,”Euro. J. Clin. Pharmacol. 31:457-462 (1986).
Stoll et al., “Choline in the Treatment of Rapid Cycling Bipolar Disorder,”Biol. Psychiatry40:382-388 (1996).
Agnoli, et al., “Efficacy of CDP choline in Chronic Cerebral Vascular Diseases (CCVD),”Novel Biochemical, Pharmacological and Clinical Aspects of CytidinediphosphocholineElsevier (1985) 305-315.
Babb et al., “Differential Effect of CDP-choline on Brain Cytosolic Choline Levels in Younger and Older Subjects as Measured by Proton Magnetic Resonance Spectroscopy,”Psychopharmacology(1996) 127:88-94.
Boudouresques, et al., “Therapeutic Conduct in Light of a Cerebral Vascular Accident and the Use of CDP-choline,”International Symposium: Brain Suffering and Precursors of Phospholipidspp. 1-12 (1980).
Brown et al., “CNS Complications of Cocaine Abuse: Prevalence, Pathophysiology, and Neuroradiology,”Am. J. Roentgenol. (1992) 159:137-147.
Centrone et al., “Use of Citicoline in High Dosages in Acute Cerebrovascular Disease,”Minerva Med. (1986) 77:371-373.
Chang et al., “Neurochemical Alterations in Asymptomatic Abstinent Cocaine Users: A Proton Magnetic Resonance Spectroscopy Study,”Biol. Psychiatry(1997) 42:1105-1114.
Christensen et al., “Abnormal Cerebral Metabolism in Polydrug Abusers During Early Withdrawal: A31P MR Spectroscopy Study,”Magn. Reson. Med. (1996) 35:658-663.
Citicoline Sodium (CDP-Choline),Investigator's Brochure, Revised: Apr. 1994 by Interneuron Pharmaceuticals, Inc.
Cohen et al., “Decreased Brain Choline Uptake in Older Adults,”JAMA(1995) 274:902-907.
English et al., “Elevated Frontal Lobe Cytosolic Choline Levels in Minimal or Mild AIDS Dementia Complex Patients: A Proton Magnetic Resonance Spectroscopy Study,”Biol. Psychiatry(1997) 41:500-502.
Gallai et al., “Study of the P300 and Cerebral Maps in Subjects with Multi-Infarct Dementia Treated with Cytidine,”Psychopharmacology(1991) 103:1-5.
Galletti et al., “Biochemical Rationale for the Use of CDP-choline in Traumatic Brain Injury. Pharmacokinetics of the Orally Administered Drug,”J. Neural. Sci. (1991) 103:S19-S25.
Hoff et al., “Effects of Crack Cocaine on Neurocognitive Function,”Psychiatry Res. (1996) 60:167-176.
Jacobs et al., “Cocaine Abuse: Neurovascular Complications,”Radiology(1989)170:223-227.
Kaufman et al., “Cocaine-Induced Cerebral Vasoconstriction Detected in Humans with Magnetic Resonance Angiography,”JAMA(1998) 279:376-380.
Kreek “Opiate and Cocaine Addictions: Challenge for Pharmacotherapies,”Pharmacol. Biochem. Behav. (1997) 57:551-569.
Levin et al., “Improved Regional Cerebral Blood Flow in Chronic Cocaine Polydrug Users Treated with Buprenorphine,”J. Nucl. Med. (1995) 36:1211-1215.
London et al., “Cerebral Glucose Utilization in Human Heroin Addicts: Case Reports from a Positron Emission Tomographic Study,”Res. Commun. Subst Abuse(1989) 10:141-144.
Lukas et al., “Effects of Short-term Citicoline Treatment on Acute Cocaine Intoxication and Cardiovascular Effects,”Psychopharmacology(2001) 157:163-7.
Maas et al., “Functional Magnetic Resonance Imaging of Human Brain Activation During Cue-induced Cocaine Craving,”Am. J. Psychiatry(1998) 155:124-126.
McCance, “Overview of Potential Treatment Medications for Cocaine Dependence,”NIDA Res. Monogr., (1997) 175:36-72.
Moglia et al., “Citico
Clark & Elbing LLP
McIntosh, III Traviss C
The McLean Hospital Corporation
LandOfFree
Compounds for the treatment of psychiatric or substance... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of psychiatric or substance..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of psychiatric or substance... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2620712